North American Menopause Society Statement Cites Dietary Isoflavones As Acceptable Treatment Option for Menopause

Novogen Launches Center for Isoflavone Research

STAMFORD, Conn., Jan 16, 2004 -- Novogen Ltd. announced today the launch of the Novogen Center for Isoflavone Research (NCIR), which seeks to provide information to the media and consumers interested in the latest available research on isoflavone consumption and related health implications.

The Center's creation comes in response to the need to meet the growing interest in research supporting the use of dietary isoflavones as a natural alternative in the treatment of many ailments associated with the aging process such as menopausal symptoms in women and Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in men.

"NCIR serves as a one-stop clearinghouse for background information on the latest in isoflavone research," said Aaron Stryker, executive director of the Center. "Researchers believe that isoflavones may hold answers to medical questions surrounding illnesses associated with aging such as cancer, menopause, and prostate complications. The Center will help to draw attention to the growing body of science supporting isoflavones."

In conjunction with its launch, NCIR has released a media kit (link to electronic files is at of isoflavone research materials supplementing the North American Menopause Society's (NAMS) position statement on the treatment of menopause symptoms released today. This comprehensive review of the science behind all major options for women suffering from menopausal symptoms concludes that supplementing behavior change with dietary isoflavones is an acceptable treatment option.

The Novogen Center for Isoflavone Research is distributing this electronic media kit ahead of its anticipated schedule, because the media materials may be of immediate use to those interested in the NAMS statement and its implication for menopausal women.

The media kit is the first of what the Center plans to be a periodic update of the information available on the research of dietary isoflavones. It offers information on the guidelines highlighted in the NAMS position statement (as well as direct access to the statement itself), the research surrounding dietary isoflavones and opportunities to speak with experts in the field. The kit also includes recommended isoflavone intake levels along with a table of methods for reaching those levels. The kit is available with this release for view electronically or can otherwise be obtained by request from any of the media contacts provided.

Based in Sydney, Australia, Novogen is the world leader in isoflavone research. The company manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. The company's lead anti-cancer compound phenoxodiol, which is based on an isoflavone-related molecule, is in several human clinical trials around the world.

CONTACT: Aaron Stryker of Novogen Center for Isoflavone Research, +1-203-327-1188 ext. 16, or David Sheon, +1-202-518-6321, for Novogen Center for Isoflavone Research.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.